Antisense Therapy

Suppression of Insulin-Like Growth Factor I Inhibits Tumorigenicity

Published in Cancer Weekly, November 3rd, 1997

Suppression of insulin-like growth factor I (IGF-I) in hepatocellular carcinoma (HCC) cells by an antisense strategy inhibits tumorigenicity and increases immunogenicity in vivo.

Current therapeutic approaches to HCC are limited and rarely result in remission rates above 15-20 percent. Research has shown that the neoplastic transformation hepatocytes undergo is accompanied by a reactivation of fetal programming with the synthesis of hepatoma-associated proteins such as (alpha)-fetoprotein and insulin-like growth factors I and II. IGF-I is associated with cellular growth and differentiation and is expressed in several tumors.

Several researchers...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly

Source: Cancer Weekly (1997-11-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry